Discovery & Innovation

At BioInvent, we combine deep immunological understanding with target-agnostic screening (when targets and structures are identified after functional activity is shown) to identify the clinically most relevant targets and antibodies for cancer immunotherapy. Patient cells, alongside our F.I.R.S.T™ technology platform and the human antibody library n-CoDeR^®, are cornerstones in this process. Fueled by cutting-edge science on the immune system and mechanisms, we identify and develop the next generation of antibody-based cancer immunotherapies.

TECHNOLOGY PLATFORMS
The unique development tool F.I.R.S.T™, where patient material is the foundation throughout the discovery & development process, identifies both clinically relevant targets and matching antibodies. The proprietary antibody library n-CoDeR^® contains antibodies that bind specifically and strongly to their targets.

TUMOR-ASSOCIATED MYELOID CELLS (TAM)
Myeloid cells are a key part of our innate, non-specific, immune system but can also be “hijacked” by tumors to support the growth and spread of cancer. Antibody-mediated “reprogramming” of immunosuppressive tumor-associated myeloid cells (TAMs), which can make up a significant fraction of the total tumor mass, is an attractive concept. BioInvent and its partners are at the forefront of this field. 

T CELLS (TREGS AND EFFECTOR T CELLS)
Effector T cells are amongst the most powerful cells of the immune system in killing tumor cells and helping prevent and cure cancer. Unfortunately, in cancer, their activity is often prevented by tumor-induced immune suppressive cells, e.g., Tregs. There are many publications showing a clear correlation between Treg abundance in tumors and poor prognosis in cancer. Conversely, effector T cell numbers and the ratio of effector T cells to Tregs correlate with survival. BioInvent is developing antibodies that target regulatory T cells and tumor-associated myeloid cells and which help expand and activate effector T cells to specifically kill cancer cells. Effector T cell activation through immune checkpoint blockade is a clinically proven concept.